TipRanks
City Therapeutics, Inc. (CTY)
NASDAQ:CTY
US Market
CTY
City Therapeutics, Inc.
RESEARCH TOOLSreports

City Therapeutics, Inc. (CTY) Ratios

6 Followers

City Therapeutics, Inc. Ratios

CTY's free cash flow for Q2 2020 was $―. For the 2020 fiscal year, CTY's free cash flow was decreased by $ and operating cash flow was $―. See a summary of the company’s cash flow.
Ratios
TTM
Dec 19Dec 18Dec 17
Liquidity Ratios
Current Ratio
 0.73 ― ―
Quick Ratio
 0.73 ― ―
Cash Ratio
 <0.01 ― ―
Solvency Ratio
 0.29 ― ―
Operating Cash Flow Ratio
 0.98 ― ―
Short-Term Operating Cash Flow Coverage
 3.02 ― ―
Net Current Asset Value
$ -8.40B$ ―$ ―
Leverage Ratios
Debt-to-Assets Ratio
 0.28 ― ―
Debt-to-Equity Ratio
 0.59 ― ―
Debt-to-Capital Ratio
 0.37 ― ―
Long-Term Debt-to-Capital Ratio
 0.32 ― ―
Financial Leverage Ratio
 2.08 ― ―
Debt Service Coverage Ratio
 2.89 ― ―
Interest Coverage Ratio
 0.00 ― ―
Debt to Market Cap
 29.56 ― ―
Interest Debt Per Share
 0.00 ― ―
Net Debt to EBITDA
 1.55 ― ―
Profitability Margins
Gross Profit Margin
70.11%――
EBIT Margin
0.00%――
EBITDA Margin
46.98%――
Operating Profit Margin
35.36%――
Pretax Profit Margin
30.26%――
Net Profit Margin
22.40%――
Continuous Operations Profit Margin
22.40%――
Net Income Per EBT
74.03%――
EBT Per EBIT
85.58%――
Return on Assets (ROA)
8.70%――
Return on Equity (ROE)
18.28%――
Return on Capital Employed (ROCE)
16.40%――
Return on Invested Capital (ROIC)
11.42%――
Return on Tangible Assets
16.35%――
Earnings Yield
0.00%――
Efficiency Ratios
Receivables Turnover
 15.87 ― ―
Payables Turnover
 6.05 ― ―
Inventory Turnover
 0.00 ― ―
Fixed Asset Turnover
 1.00 ― ―
Asset Turnover
 0.39 ― ―
Working Capital Turnover Ratio
 -12.09 ― ―
Cash Conversion Cycle
 -37.33 ― ―
Days of Sales Outstanding
 23.00 ― ―
Days of Inventory Outstanding
 0.00 ― ―
Days of Payables Outstanding
 60.33 ― ―
Operating Cycle
 23.00 ― ―
Cash Flow Ratios
Operating Cash Flow Per Share
 0.00 ― ―
Free Cash Flow Per Share
 0.00 ― ―
CapEx Per Share
 0.00 ― ―
Free Cash Flow to Operating Cash Flow
 0.68 ― ―
Dividend Paid and CapEx Coverage Ratio
 1.25 ― ―
Capital Expenditure Coverage Ratio
 3.16 ― ―
Operating Cash Flow Coverage Ratio
 0.56 ― ―
Operating Cash Flow to Sales Ratio
 0.41 ― ―
Free Cash Flow Yield
1130.88%――
Valuation Ratios
Price-to-Earnings (P/E) Ratio
 0.00 ― ―
Price-to-Sales (P/S) Ratio
 0.02 ― ―
Price-to-Book (P/B) Ratio
 0.00 ― ―
Price-to-Free Cash Flow (P/FCF) Ratio
 0.09 ― ―
Price-to-Operating Cash Flow Ratio
 0.00 ― ―
Price-to-Earnings Growth (PEG) Ratio
 0.00 ― ―
Enterprise Value Multiple
 1.60 ― ―
Enterprise Value
 6.15B ― ―
EV to EBITDA
 1.60 ― ―
EV to Sales
 0.75 ― ―
EV to Free Cash Flow
 2.70 ― ―
EV to Operating Cash Flow
 1.85 ― ―
Tangible Book Value Per Share
 0.00 ― ―
Shareholders’ Equity Per Share
 0.00 ― ―
Tax and Other Ratios
Effective Tax Rate
 0.26 ― ―
Revenue Per Share
 0.00 ― ―
Net Income Per Share
 0.00 ― ―
Tax Burden
 0.74 ― ―
Interest Burden
 0.00 ― ―
Research & Development to Revenue
 0.00 ― ―
SG&A to Revenue
 0.08 ― ―
Stock-Based Compensation to Revenue
 <0.01 ― ―
Income Quality
 1.82 ― ―
Currency in USD